- Conditions
- Prostatic Neoplasm
- Interventions
- AAA617, AAA517, Piflufolastat F 18, ARPI, ADT, Best supportive care
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Athens, Georgia • Indianapolis, Indiana + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 97
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Cancer
- Interventions
- 68Ga-HBED-CC-PSMA
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Prostate Cancer
- Interventions
- 68Ga-PSMA-11 PET-MRI
- Diagnostic Test
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- Carmel, Indiana • Indianapolis, Indiana
- Conditions
- Prostate Cancer
- Interventions
- Multiple Dose of 225Ac-J591 at 45 KBq/kg, Multiple Dose of 225Ac-J591 at 55 KBq/kg, Multiple Dose of 225Ac-J591 at 65 KBq/kg, Fractionated Dose of 225Ac-J591 at 45 KBq/kg, Fractionated Dose of 225Ac-J591 at 55 KBq/kg, Fractionated Dose of 225Ac-J591 at 60 KBq/kg, Fractionated Dose of 225Ac-J591 at 65 KBq/kg, Fractionated Dose of 225Ac-J591 at 45 KBq/kg (Prior 177Lu-PSMA-RL), Fractionated Dose of 225Ac-J591 at 50 KBq/kg (Prior 177Lu-PSMA-RL), 68Ga-PSMA-HBED-CC injection
- Drug · Diagnostic Test
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Brooklyn, New York • New York, New York
- Conditions
- Prostate Cancer
- Interventions
- Ga-68 labeled PSMA-11, Positron emission tomography-computed tomography (PET/CT), Positron emission tomography-magnetic resonance imaging (PET/MRI)
- Drug · Device
- Lead sponsor
- Thomas Hope
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Prostate Carcinoma
- Interventions
- Biopsy of Prostate, Gallium Ga 68 Gozetotide, Transrectal Ultrasonography Guided Biopsy
- Procedure · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 90 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography
- Procedure · Other · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostate Cancer
- Interventions
- 68Ga-PSMA
- Drug
- Lead sponsor
- Ebrahim Delpassand
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- Ga-PSMA-11
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Denver, Colorado
- Conditions
- Metastatic Adenoid Cystic Carcinoma
- Interventions
- Computed Tomography, Electronic Health Record Review, Ga-68 PSMA-11, Positron Emission Tomography
- Procedure · Other · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Prostatic Neoplasms
- Interventions
- (68Ga)PSMA-HBED-CC
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Procedure · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Thyroid Gland Carcinoma
- Interventions
- Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging, Positron Emission Tomography (PET)
- Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Metastatic to Bone
- Interventions
- 68Ga PSMA-11 injection, Positron Emission Tomography/Computed Tomography
- Drug · Procedure
- Lead sponsor
- Dana Mathews
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Prostate Cancer
- Interventions
- PET/MRI with Gallium-68 labeled PSMA-HBED-CC, Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC, PET/CT with Gallium-68 labeled PSMA-HBED-CC
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Adenocarcinoma, PSA Progression, Recurrent Prostate Carcinoma
- Interventions
- Gallium Ga 68 DOTA-NeoBOMB1, Gallium Ga 68 PSMA-R2
- Drug · Device
- Lead sponsor
- Andrei Iagaru
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Metastatic Prostate Cancer
- Interventions
- [68Ga]PSMA-PET/MRI or PET/CT
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Biopsy, Computed Tomography, Gallium Ga 68 Gozetotide, Magnetic Resonance Imaging, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Gallium Ga 68 Gozetotide, Hepatic Artery Embolization, Positron Emission Tomography and Computed Tomography Scan
- Radiation · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Metastatic, Prostate Cancer Recurrent
- Interventions
- 68Ga-PSMA
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,435 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Prostate Cancer, Prostatic Neoplasm, Prostatic Neoplasms, Castration-Resistant, Prostatic Cancer Recurrent, Prostatic Cancer Metastatic
- Interventions
- Ga-68 PSMA-HBED-CC PET
- Drug
- Lead sponsor
- Michael Graham PhD, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Prostate Adenocarcinoma, PSA Failure, Recurrent Prostate Carcinoma
- Interventions
- Computed Tomography (CT) scan, 68Ga-PSMA-11, Positron Emission Tomography (PET)
- Procedure · Drug
- Lead sponsor
- Andrei Iagaru
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Oligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma
- Interventions
- Actinium Ac 225 Vipivotide Tetraxetan, Biospecimen Collection, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, PSMA PET-CT Scan, Stereotactic Body Radiation Therapy
- Drug · Procedure · Other + 1 more
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
- Interventions
- Gallium Ga 68 Gozetotide, Laboratory Biomarker Analysis, Positron Emission Tomography
- Radiation · Other · Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 1,138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California